The intensity of these symptoms is typically mild to moderate and tends to diminish over time as your body adjusts to the medication, particularly if dose escalation proceeds gradually
Ozempic is not indicated for weight loss Rate of MACE events by weight-loss category with 95% CI SUSTAIN 6: Post hoc analysis 3 Study design: The primary objective of the observational, post hoc analysis of SUSTAIN 6 was to examine the incidence rate of 3-point major adverse cardiovascular events (MACE) (nonfatal ischemic stroke, nonfatal MI, and CV death) by weight-loss categories during the first 13 months after initiation of Ozempic injection (N=1479)
These are not interchangeable medications
For more information: Christopher T
A similar pattern was seen with tirzepatide in the SURMOUNT-4 trial participants who switched from tirzepatide to placebo regained a substantial portion of their weight over 36 weeks
Moradi S, Bagheri R, Amirian P, Zarpoosh M, Cheraghloo N, Wong A, et al